Regeneron Pharmaceuticals Statistics
Total Valuation
REGN has a market cap or net worth of $81.43 billion. The enterprise value is $65.54 billion.
| Market Cap | 81.43B |
| Enterprise Value | 65.54B |
Important Dates
The last earnings date was Friday, January 30, 2026, before market open.
| Earnings Date | Jan 30, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
REGN has 102.62 million shares outstanding. The number of shares has decreased by -5.65% in one year.
| Current Share Class | 100.80M |
| Shares Outstanding | 102.62M |
| Shares Change (YoY) | -5.65% |
| Shares Change (QoQ) | +0.28% |
| Owned by Insiders (%) | 3.79% |
| Owned by Institutions (%) | 87.31% |
| Float | 98.55M |
Valuation Ratios
The trailing PE ratio is 19.13 and the forward PE ratio is 17.76. REGN's PEG ratio is 2.04.
| PE Ratio | 19.13 |
| Forward PE | 17.76 |
| PS Ratio | 5.79 |
| Forward PS | 5.18 |
| PB Ratio | 2.60 |
| P/TBV Ratio | 2.71 |
| P/FCF Ratio | 19.96 |
| P/OCF Ratio | 16.36 |
| PEG Ratio | 2.04 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.44, with an EV/FCF ratio of 16.06.
| EV / Earnings | 14.55 |
| EV / Sales | 4.57 |
| EV / EBITDA | 15.44 |
| EV / EBIT | 17.70 |
| EV / FCF | 16.06 |
Financial Position
The company has a current ratio of 4.13, with a Debt / Equity ratio of 0.10.
| Current Ratio | 4.13 |
| Quick Ratio | 3.28 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.69 |
| Debt / FCF | 0.73 |
| Interest Coverage | 84.52 |
Financial Efficiency
Return on equity (ROE) is 14.87% and return on invested capital (ROIC) is 12.54%.
| Return on Equity (ROE) | 14.87% |
| Return on Assets (ROA) | 5.91% |
| Return on Invested Capital (ROIC) | 12.54% |
| Return on Capital Employed (ROCE) | 10.23% |
| Weighted Average Cost of Capital (WACC) | 6.34% |
| Revenue Per Employee | $930,753 |
| Profits Per Employee | $292,336 |
| Employee Count | 15,410 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 2.53 |
Taxes
In the past 12 months, REGN has paid $725.80 million in taxes.
| Income Tax | 725.80M |
| Effective Tax Rate | 13.88% |
Stock Price Statistics
The stock price has increased by +17.80% in the last 52 weeks. The beta is 0.41, so REGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +17.80% |
| 50-Day Moving Average | 761.24 |
| 200-Day Moving Average | 629.25 |
| Relative Strength Index (RSI) | 58.10 |
| Average Volume (20 Days) | 840,906 |
Short Selling Information
The latest short interest is 2.18 million, so 2.12% of the outstanding shares have been sold short.
| Short Interest | 2.18M |
| Short Previous Month | 2.29M |
| Short % of Shares Out | 2.12% |
| Short % of Float | 2.21% |
| Short Ratio (days to cover) | 2.49 |
Income Statement
In the last 12 months, REGN had revenue of $14.34 billion and earned $4.50 billion in profits. Earnings per share was $41.48.
| Revenue | 14.34B |
| Gross Profit | 6.39B |
| Operating Income | 3.70B |
| Pretax Income | 5.23B |
| Net Income | 4.50B |
| EBITDA | 4.25B |
| EBIT | 3.70B |
| Earnings Per Share (EPS) | $41.48 |
Balance Sheet
The company has $8.61 billion in cash and $2.97 billion in debt, with a net cash position of $15.89 billion or $154.87 per share.
| Cash & Cash Equivalents | 8.61B |
| Total Debt | 2.97B |
| Net Cash | 15.89B |
| Net Cash Per Share | $154.87 |
| Equity (Book Value) | 31.26B |
| Book Value Per Share | 304.65 |
| Working Capital | 13.65B |
Cash Flow
In the last 12 months, operating cash flow was $4.98 billion and capital expenditures -$898.40 million, giving a free cash flow of $4.08 billion.
| Operating Cash Flow | 4.98B |
| Capital Expenditures | -898.40M |
| Free Cash Flow | 4.08B |
| FCF Per Share | $39.76 |
Margins
Gross margin is 44.57%, with operating and profit margins of 25.81% and 31.41%.
| Gross Margin | 44.57% |
| Operating Margin | 25.81% |
| Pretax Margin | 36.47% |
| Profit Margin | 31.41% |
| EBITDA Margin | 29.60% |
| EBIT Margin | 25.81% |
| FCF Margin | 28.45% |
Dividends & Yields
This stock pays an annual dividend of $3.76, which amounts to a dividend yield of 0.47%.
| Dividend Per Share | $3.76 |
| Dividend Yield | 0.47% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 8.63% |
| Buyback Yield | 5.65% |
| Shareholder Yield | 6.12% |
| Earnings Yield | 5.53% |
| FCF Yield | 5.01% |
Analyst Forecast
The average price target for REGN is $812.57, which is 2.40% higher than the current price. The consensus rating is "Buy".
| Price Target | $812.57 |
| Price Target Difference | 2.40% |
| Analyst Consensus | Buy |
| Analyst Count | 23 |
| Revenue Growth Forecast (5Y) | 8.35% |
| EPS Growth Forecast (5Y) | 12.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGN has an Altman Z-Score of 6.51 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.51 |
| Piotroski F-Score | 4 |